Loading
AMEXHealthcareMedical - Pharmaceuticals
Latest quote
$3.69
−$0.085 · -2.25%
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Regular session
$3.69
−$0.085 · -2.25%
Regular session · ET · Market data may be delayed.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Day range
Current $3.69
52-week range
Current $3.69
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
48
Fair Value
Sentiment
43
Mixed
Risk
96
Extreme Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Day range
Current $3.69
52-week range
Current $3.69
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 2.24M USD | 335K USD | 567K USD | 1.12M USD |
| Selling, general, and administrative | 2.67M USD | 743K USD | 580K USD | 926K USD |
| Operating expenses | 4.9M USD | 1.08M USD | 1.15M USD | 2.04M USD |
| Interest expense | — | 29K USD | 49K USD | 18K USD |
| Operating income | −4.9M USD | −1.08M USD | −1.15M USD | −2.04M USD |
| Net income | −5.86M USD | −1.53M USD | −1.05M USD | −1.71M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$22.00
496.21% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
